Latest Intelligence on Pharmaceuticals and Healthcare in Austria

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Vaccines: Intercell buys Iomai

Intercell has acquired Iomai for $189 million, in a deal motivated by the Austrian company's desire to gain ownership of Iomai's traveler's diarrhea vaccine and transdermal delivery technology. With the potential to deliver both vaccine and adjuvant, independently, through Iomai's transdermal patch, Intercell's development of its proprietary adjuvant IC31 may also benefit from the technology.

Published By Datamonitor
13 May 2008
CommentWire
CommentWire

Novartis: increasing presence in vaccines

Thanks to a new deal with Intercell, Novartis is set to gain access to several vaccine candidates, including those for the prevention of pneumonia in elderly and infants, and hospital-acquired Pseudomonas. After several agreements with other companies and the acquisition of Chiron in 2006, it appears Novartis is on its way to becoming a major infectious diseases player.

Published By Datamonitor
02 Jul 2007
CommentWire
CommentWire

Schering-Plough/Centocor: wider Remicade indication

Published By Datamonitor
06 Feb 2001

« | 1 | » »|

No help is available.